

Application Serial No. Unassigned  
Attorney's Docket No. 033025-002  
Page 8

**REMARKS**

Entry of the foregoing and favorable consideration of the subject application, in light of the following remarks, are respectfully requested.

By the present amendment, the claims have been amended to place them in the proper format for examination. Each of the added claims corresponds to a claim in the International application. No new matter has been added by the present amendment.

In the event that there are any questions relating to this Preliminary Amendment, or the application in general, it would be appreciated if the Examiner would telephone the undersigned attorney concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: \_\_\_\_\_


  
Dawn M. Gardner  
Registration No. 44,118

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: December 12, 2001

ABSTRACT OF THE INVENTION

The present invention relates to an aminophenoxyacetamide derivative of the formula (I):



wherein  $R^1$  to  $R^4$  are, independent from each other, a hydrogen atom or an optionally substituted alkyl group;  $E^1$  is  $-NR^4-$ ; and  $E^2$  is an oxygen atom or  $-NR^{10}-$ ;  $Q$  is the group - $X-Y-Q'$ , wherein  $X$  and  $Y$  are connecting bonds or  $X$  is an alkylene or alkenylene group and  $Y$  is selected from a group comprising  $C=O$ ,  $NHC(=O)$ , and  $C(=O)NH$ , and  $Q'$  is a hydrogen atom or a phenyl or pyridyl group which may be substituted; and pharmaceutically acceptable salts thereof. The present invention further relates to compositions comprising compounds of the formula (I) and methods of using said compounds for treating cerebral functional disorders and cerebral organic disorders.

Application No. To be assigned  
Attorney's Docket No. 033025-002  
Page 1

**Attachment to Preliminary Amendment dated December 13, 2001**

**Marked-up Copy**

Page 3, Paragraph Beginning at Line 13

--On the other hand, the lower molecular weight compounds capable of [including] inducing the production of CalbindinD-28k protein can be easily prepared into the various kinds of pharmaceutical compositions by the conventional technique. Therefore, these lower molecular weight compounds would induce the production of the neuroprotective CalbindinD-28k protein once easily administered into a body, showing the buffering action against the increase of the intracellular  $\text{Ca}^{2+}$  concentration. That is, these lower molecular weight compounds can be effective pharmaceutical compounds for improving and treating cerebral functional and organic disorders.--